Stimulant drugs acting at the dopamine transporter (DAT), like cocaine, are widely abused,
yet effective medical treatments for this abuse have not been found. Analogs of benztropine …

The dopamine transporter (DAT) has been a primary target for cocaine abuse/addiction
medicationdiscovery. However predicted addiction liability and limited clinical evaluation …

Rationale: Previous SAR studies demonstrated that small halogen substitutions on the
diphenylether system of benztropine (BZT), such as a para-Cl group, retained high affinity at …

There is a large unmet medical need for cocaine addiction treatments. Studies have
indicated that the dopamine transporter (DAT) is the primary biological target of cocaine, and …

Both in vitro binding studies and studies of dopamine uptake have indicated that there is a
heterogeneity of action of cocaine and cocaine analogs. Both high-and low-affinity binding …

Previous studies demonstrated that analogs of benztropine (BZT) possess high affinity for
the dopamine transporter, inhibit dopamine uptake, but generally have behavioral effects …

In an attempt to discover a cocaine‐abuse pharmacotherapeutic, extensive investigation has
been directed toward elucidating the molecular mechanisms underlying the reinforcing …

An N-butyl analog of benztropine, JHW007 [N-(n-butyl)-3 α-[bis (4′-fluorophenyl) methoxy]-
tropane], binds to dopamine transporters (DAT) but has reduced cocaine-like behavioral …

Drugs that inhibit dopamine (DA) reuptake through actions at the dopamine transporter
(DAT) have been proposed as candidates for development as pharmacotherapies for …

The current studies evaluated the novel diphenylmethoxytropane analog 4-
chlorobenztropine (4-Cl-BZT), cocaine, and combinations of the two drugs for their abilities …